These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

728 related items for PubMed ID: 17352646

  • 1. Cinacalcet in the management of tumor-induced osteomalacia.
    Geller JL, Khosravi A, Kelly MH, Riminucci M, Adams JS, Collins MT.
    J Bone Miner Res; 2007 Jun; 22(6):931-7. PubMed ID: 17352646
    [Abstract] [Full Text] [Related]

  • 2. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets.
    Alon US, Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD.
    Clin J Am Soc Nephrol; 2008 May; 3(3):658-64. PubMed ID: 18256372
    [Abstract] [Full Text] [Related]

  • 3. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism.
    Serra AL, Wuhrmann C, Wüthrich RP.
    Am J Kidney Dis; 2008 Dec; 52(6):1151-7. PubMed ID: 18950915
    [Abstract] [Full Text] [Related]

  • 4. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM, Wetmore JB, Gurevich K, Da Roza G, Buerkert J, Reiner M, Goodman W, Cooper K.
    Clin J Am Soc Nephrol; 2015 Jun 05; 10(6):1021-30. PubMed ID: 25873267
    [Abstract] [Full Text] [Related]

  • 5. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
    Arai R, Onodera T, Terkawi MA, Mitsuhashi T, Kondo E, Iwasaki N.
    BMC Musculoskelet Disord; 2017 Feb 13; 18(1):79. PubMed ID: 28193220
    [Abstract] [Full Text] [Related]

  • 6. Renal Phosphate Wasting Due to Tumor-Induced (Oncogenic) Osteomalacia.
    Amaratunga EA, Ernst EB, Kamau J, Kotala R, Snyder R.
    Cureus; 2021 Jun 13; 13(6):e15507. PubMed ID: 34268038
    [Abstract] [Full Text] [Related]

  • 7. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.
    Harrell RM, Lyles KW, Harrelson JM, Friedman NE, Drezner MK.
    J Clin Invest; 1985 Jun 13; 75(6):1858-68. PubMed ID: 3839245
    [Abstract] [Full Text] [Related]

  • 8. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?
    Bhan I, Shah A, Holmes J, Isakova T, Gutierrez O, Burnett SM, Jüppner H, Wolf M.
    Kidney Int; 2006 Oct 13; 70(8):1486-94. PubMed ID: 16941023
    [Abstract] [Full Text] [Related]

  • 9. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.
    Finch JL, Tokumoto M, Nakamura H, Yao W, Shahnazari M, Lane N, Slatopolsky E.
    Am J Physiol Renal Physiol; 2010 Jun 13; 298(6):F1315-22. PubMed ID: 20200094
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
    Drezner MK, Lyles KW, Haussler MR, Harrelson JM.
    J Clin Invest; 1980 Nov 13; 66(5):1020-32. PubMed ID: 6253520
    [Abstract] [Full Text] [Related]

  • 11. Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy.
    Ovejero D, El-Maouche D, Brillante BA, Khosravi A, Gafni RI, Collins MT.
    J Bone Miner Res; 2017 Aug 13; 32(8):1667-1671. PubMed ID: 28459498
    [Abstract] [Full Text] [Related]

  • 12. Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D.
    Collins MT, Lindsay JR, Jain A, Kelly MH, Cutler CM, Weinstein LS, Liu J, Fedarko NS, Winer KK.
    J Bone Miner Res; 2005 Nov 13; 20(11):1944-50. PubMed ID: 16234967
    [Abstract] [Full Text] [Related]

  • 13. Phosphaturic mesenchymal tumors: what an endocrinologist should know.
    Boland JM, Tebben PJ, Folpe AL.
    J Endocrinol Invest; 2018 Oct 13; 41(10):1173-1184. PubMed ID: 29446010
    [Abstract] [Full Text] [Related]

  • 14. Tumor-induced osteomalacia: lessons learned.
    Lewiecki EM, Urig EJ, Williams RC.
    Arthritis Rheum; 2008 Mar 13; 58(3):773-7. PubMed ID: 18311810
    [Abstract] [Full Text] [Related]

  • 15. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.
    Chertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM, Reed J, CONTROL Investigators.
    Clin J Am Soc Nephrol; 2006 Mar 13; 1(2):305-12. PubMed ID: 17699221
    [Abstract] [Full Text] [Related]

  • 16. Effects of cinacalcet in renal transplant patients with hyperparathyroidism.
    Courbebaisse M, Diet C, Timsit MO, Mamzer MF, Thervet E, Noel LH, Legendre C, Friedlander G, Martinez F, Prié D.
    Am J Nephrol; 2012 Mar 13; 35(4):341-8. PubMed ID: 22473131
    [Abstract] [Full Text] [Related]

  • 17. FGF-23 is elevated by chronic hyperphosphatemia.
    Gupta A, Winer K, Econs MJ, Marx SJ, Collins MT.
    J Clin Endocrinol Metab; 2004 Sep 13; 89(9):4489-92. PubMed ID: 15356053
    [Abstract] [Full Text] [Related]

  • 18. Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.
    Sánchez Fructuoso AI, Maestro ML, Calvo N, De La Orden V, Pérez Flores I, Vidaurreta M, Valero R, Fernández-Pérez C, Barrientos A.
    Transplant Proc; 2012 Nov 13; 44(9):2551-4. PubMed ID: 23146451
    [Abstract] [Full Text] [Related]

  • 19. Emerging role of a phosphatonin in mineral homeostasis and its derangements.
    Bielesz B.
    Eur J Clin Invest; 2006 Aug 13; 36 Suppl 2():34-42. PubMed ID: 16884396
    [Abstract] [Full Text] [Related]

  • 20. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ, Bravo Soto JA, Merino Pérez MJ, González Carmelo I, López Jiménez V, García Álvarez T, Acosta Martínez Y, Mazuecos Blanca MA.
    Nefrologia; 2015 Aug 13; 35(4):363-73. PubMed ID: 26306956
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.